Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Oct;54(10):4503-5.
doi: 10.1128/AAC.01707-09. Epub 2010 Jul 26.

Colistin dosing and nephrotoxicity in a large community teaching hospital

Affiliations

Colistin dosing and nephrotoxicity in a large community teaching hospital

C Andrew Deryke et al. Antimicrob Agents Chemother. 2010 Oct.

Abstract

Thirty adult patients who received intravenous colistin (5.1 ± 2.4 mg/kg/day) were reviewed to evaluate dosing with respect to nephrotoxicity, which occurred in 10 (33%) patients within the first 5 days of treatment. Excessive colistin dosing was frequent (47%), often (71%) resulted from the use of actual body weight in obese patients, and was associated with higher rates of nephrotoxicity (80% versus 30%, P = 0.019).

PubMed Disclaimer

References

    1. Cockcroft, D. W., and M. H. Gault. 1976. Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41. - PubMed
    1. Devine, B. 1974. Gentamicin therapy. Drug Intell. Clin. Pharm. 8:650-655.
    1. Evans, M. E., D. J. Feola, and R. P. Rapp. 1999. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann. Pharmacother. 33:960-967. - PubMed
    1. Falagas, M. E., K. N. Fragoulis, S. K. Kasiakou, G. J. Sermaidis, and A. Michalopoulos. 2005. Nephrotoxicity of intravenous colistin: a prospective evaluation. Int. J. Antimicrob. Agents 26:504-507. - PubMed
    1. Falagas, M. E., S. K. Kasiakou, D. P. Kofteridis, G. Roditakis, and G. Samonis. 2006. Effectiveness and nephrotoxicity of intravenous colistin for treatment of patients with infections due to polymyxin-only-susceptible (POS) gram-negative bacteria. Eur. J. Clin. Microbiol. Infect. Dis. 25:596-599. - PubMed